Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release

Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in B cell malignancies. However, high tumor burden limits clinical efficacy and increases the risk of cytokine release syndrome and neurotoxicity, which is associated with over-activation of the CAR-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ang, Sun, Yao, Du, Jie, Dong, Yansheng, Pang, Honggang, Ma, Lei, Si, Shaoyan, Zhang, Zhong, He, Mingyi, Yue, Yang, Zhang, Xiaoli, Zhao, Weichao, Pi, Jianjun, Chang, Mindong, Wang, Quanjun, Zhang, Yikun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524077/
https://www.ncbi.nlm.nih.gov/pubmed/34675920
http://dx.doi.org/10.3389/fimmu.2021.724211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524077/
https://www.ncbi.nlm.nih.gov/pubmed/34675920
http://dx.doi.org/10.3389/fimmu.2021.724211

Ejemplares similares